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Background: Cubilin is an endocytic receptor that is necessary for renal and intestinal absorption of a range of
ligands. Endocytosis mediated by cubilin and its co-receptor megalin is the principal mechanism for proximal
tubule reabsorption of proteins from the glomerular filtrate. Cubilin is also required for intestinal endocytosis of
intrinsic factor-vitamin B12 complex. Despite its importance, little is known about the regulation of cubilin
expression.
Results: Here we show that cubilin expression is under epigenetic regulation by at least two processes. The first
process involves inactivation of expression of one of the cubilin alleles. This monoallelic expression state could not
be transformed to biallelic by inhibiting DNA methylation or histone deacetylation. The second process involves
transcriptional regulation of cubilin by peroxisome proliferator-activated receptor (PPAR) transcription factors that
are themselves regulated by DNA methylation and histone deacetylation. This is supported by findings that
inhibitors of DNA methylation and histone deacetylation, 5Aza and TSA, increase cubilin mRNA and protein in renal
and intestinal cell lines. Not only was the expression of PPARα and γ inducible by 5Aza and TSA, but the positive
effects of TSA and 5Aza on cubilin expression were also dependent on both increased PPAR transcription and
activation. Additionally, 5Aza and TSA had similar effects on the expression of the cubilin co-receptor, megalin.
Conclusions: Together, these findings reveal that cubilin and megalin mRNA expression is under epigenetic control
and thus point to new avenues for overcoming pathological suppression of these genes through targeting of
epigenetic regulatory processes.
Keywords: Cubilin, Megalin, LRP-2, Amnionless, Albumin, Epigenetic, Monoallelic expression, CpG Island, DNA
Methylation, 5-Azacytidine, 5Aza, Trichostatin A, TSA, Histone hypoacetylation, Histone deacetylase, HDAC,
Peroxisome proliferator-activated receptor, PPAR, Kidney, Proximal tubule, Intestine, EnterocyteBackground
Cubilin is a 460-kDa peripheral membrane glycoprotein,
anchored to the plasma membrane via an amino ter-
minal amphipathic helix [1,2] and through interactions
with the transmembrane protein, amnionless, forming
the so-called cubam complex [3,4]. Cubilin is expressed
by the absorptive epithelia of tissues such as renal prox-
imal convoluted tubules [5], ileum [6], and yolk sac [7],
where it mediates the endocytosis of numerous ligands
[1], in some cases acting in concert with another
endocytic receptor, LRP-2/megalin [8].
Cubilin was first described as the intrinsic factor-
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reproduction in any medium, provided the orabsorption of vitamin B12 [9]. Mutations of the cubilin
gene are the cause of Imerslund-Gräsbeck syndrome,
also known as selective vitamin B12 malabsorption with
proteinuria [10]. Proteinuria in these individuals results
from the inability of the cubilin-deficient kidney to
reabsorb ligands that filter across the glomerulus, in-
cluding albumin and apolipoprotein A-I, the major apo-
lipoprotein of HDL [11,12].
In vitro studies have shown that cubilin mRNA ex-
pression is stimulated by retinoic acid and that it is not
sterol-regulated [8]. Cubilin is co-expressed with megalin
in numerous tissues [7,8,13,14], suggesting the possibility
that the genes share common transcriptional regulatory
mechanisms. Peroxisome proliferator-activated receptors
(PPARs), transcription factors belonging to the nuclear re-
ceptor superfamily, upregulate megalin expression [15],Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cubilin expression. Furthermore, expression of megalin is
regulated by histone acetylation and methylation and
DNA methylation [16], but it is not yet known whether
cubilin is regulated epigenetically in a similar manner.
The availability of a mouse carrying a knockin of an
EGFP cassette into the cubilin gene [17] has enabled
precise histological analysis of cubilin expression. While
evaluating cubilin-EGFP expression in renal tissue of
mice heterozygous for the knockin allele, we observed a
striking difference in the distribution of EGFP immunore-
activity versus cubilin immunoreactivity. Although both
were detected at sites that matched cubilin distribution in
wildtype animals, the cellular distributions in heterozygous
mice were largely exclusive such that cells appeared to ex-
press predominantly either EGFP or cubilin. This led us to
postulate that cubilin might undergo an allelic inactivation
that silenced or strongly diminished expression of either
the maternal or paternal allele. This phenomenon, called
monoallelic expression [18], can occur through chromo-
somal inactivation (e.g., X inactivation), autosomal gene
imprinting or random gene inactivation [19]. Monoallelic
expression of a variety of autosomal genes have been
described [19,20], including p120 catenin [21], certain cy-
tokines [22], olfactory receptors and antigen receptors
[23,24]. Here we explored the possibility that cubilinFigure 1 Monoallelic expression of cubilin in Cubn+/del exon 1–6;EGFP mic
deficient renal proximal tubules cells. A shows a confocal micrograph o
and the nuclear stain, Draq5. B shows a confocal image from a section of a
Draq5. Asterisks indicate proximal tubules displaying relatively low levels of
cubilin immunolabeling (red) and anti-EGFP immunolabeling (green) and nu
in C. E and G show confocal images of anti-albumin labeled sections from
show images of the sections shown in E and G merged with anti-EGFP lab(Cubn), an autosomal gene [25], is regulated through epi-
genetic mechanisms and whether such processes might
have consequences on cubilin function and on the expres-
sion of its partners, amnionless and megalin.
Results
Monoallelic expression of cubilin in the renal proximal
tubules
Kidney sections from wildtype mice and mice heterozy-
gous for Cubn exon 1–6 deletion with an EGFP cassette
insertion (Cubn+/del exon 1–6;EGFP) were immunolabeled
with antibodies to cubilin and EGFP. In kidneys from
wildtype mice, all proximal tubules displayed prominent
and relatively uniform brush border immunolabeling
with anti-cubilin IgG (Figure 1A). By contrast, the
kidneys of Cubn+/del exon 1–6;EGFP mice showed strong
immunolabeling in the brush border regions of only a
subset of proximal tubules (Figure 1B). Evaluation of
EGFP immunolabeling in kidney sections from these
mice revealed a similar discontinuous distribution, with
some cells showing high levels of anti-EGFP immuno-
fluorescence while adjacent cells had only weak fluores-
cence (Figure 1C). However, strikingly, the epithelial
cells that had strong EGFP immunofluorescence
displayed little or no cubilin immunolabeling (Figure 1D).
Conversely, the proximal tubules that showed relativelye leads to reduced albumin binding to brush borders of cubilin-
f a section of wildtype mouse kidney labeled with anti-cubilin IgG (red)
Cubn+/del exon 1–6;EGFP mouse kidney labeled with anti-cubilin and
anti-cubilin immunolabeling. C and D are merged images of anti-
clear staining (blue). D is a digitally zoomed in view of the boxed area
wildtype (E) and Cubn+/del exon 1–6;EGFP (F) mouse kidneys. F and H
eling. G, glomerulus.
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cubilin immunolabeling. Similar observations were made
in the kidneys of female Cubn+/del exon 1–6;EGFP mice
(data not shown). Thus, in the proximal tubule cells of
Cubn+/del exon 1–6;EGFP mice, the level of EGFP immuno-
fluorescence was inversely related to the level of cubilin
immunofluorescence. These observations suggest that one
of the two cubilin alleles in these heterozygous mice, ei-
ther the targeted deletion/EGFP insertion allele or the
wild-type cubilin allele, is suppressed while the remaining
allele is active. Collectively, the findings suggest that the
cubilin gene is subject to monoallelic inactivation in the
kidney. The allelic inactivation appears to be stochastic in
that adjacent proximal tubule cells could be found in
which one cell was expressing high levels of EGFP and the
other not. The fact that most proximal tubule cells in
Cubn+/del exon 1–6;EGFP kidneys were not completely devoid
of EGFP immunofluorescence suggests that the inactiva-
tion process is not absolute.
EGFP expressing, cubilin deficient proximal tubule cells
display reduced albumin localization in
Cubn+/del exon 1–6;EGFP mice
Cubilin located on the brush border of renal proximal
tubule cells mediates binding and endocytosis of albumin
from the glomerular filtrate [12]. In kidneys of wildtypeFigure 2 Megalin expression is uniform whereas amnionless accumulate
mice. A-C show confocal images of a section of Cubn+/del exon 1–6;EGFP mou
merged image of anti-megalin and anti-cubilin immunolabeling together w
example of a proximal tubule displaying strong anti-megalin immunolabeli
from a section of a Cubn+/del exon 1–6;EGFP mouse kidney labeled with anti-amn
mouse kidney shown in D labeled with anti-amnionless, anti-cubilin and the
areas in D and E showing a proximal tubule displaying strong anti-cubilin imm
cubilin labeling. Arrowheads indicate intracellular accumulations of Amn immmice, albumin is localized on the apical/brush border
regions of renal proximal tubules (Figure 1E and F). In
Cubn+/del exon 1–6;EGFP mice, pronounced albumin
immunolabeling was apparent in the apical/brush
border regions of a subset of renal proximal tubules
that showed relatively low EGFP immunofluorescence
(Figure 1G and H). By contrast, proximal tubules with
strong anti-EGFP immunofluorescence showed little or
no albumin immunolabeling in the brush border region.
These findings suggest that the cubilin-deficient proximal
tubules (i.e., those cells with strong anti-EGFP immuno-
fluorescence) are unable to efficiently bind and endocytose
albumin, which is consistent with other studies showing
that cubilin deficiency leads to albuminuria [12,26].
Expression of megalin and amnionless in the kidney of
Cubn+/del exon 1–6;EGFP mice
We next evaluated the expression of two cubilin-binding
membrane proteins, megalin and amnionless, in prox-
imal tubules of Cubn+/del exon 1–6;EGFP mice. As shown in
Figure 2A, anti-megalin immunolabeling was relatively
uniform in the brush border regions of all proximal
tubules. Furthermore, the relative levels of megalin
immunolabeling were uniform among all proximal tu-
bules, irrespective of the varied levels of anti-cubilin
immunolabeling (Figure 2A and B boxed areas). Baseds in cubilin-deficient renal proximal tubules of Cubn+/del exon 1–6;EGFP
se kidney labeled with anti-megalin IgG (A), anti-cubilin (B). C is a
ith Draq5 nuclear staining (blue). Boxed areas in A and B highlight an
ng and relatively weak anti-cubilin labeling. D shows a confocal image
ionless (Amn). E is a merged image of the section of Cubn+/del exon 1–6;EGFP
nuclear stain, Draq5 (blue). F is a digitally zoomed in view of the boxed
unolabeling adjacent to two proximal tubules with little or no anti-
unolabeling. G, glomerulus.
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monoallelic inactivation in Cubn+/del exon 1–6;EGFP mice
apparently has no effect on the expression of megalin in
the renal proximal tubule brush border. By contrast, im-
munofluorescence analysis of amnionless showed that in
proximal tubules having little or no anti-cubilin labeling,
amnionless accumulated within the proximal tubule cells
as compared to proximal tubule cells having high levels
of anti-cubilin labeling (Figure 2D-F). These findings are
consistent with previous studies showing that cubilin
prevents intracellular accumulation of amnionless [27].
Expression of cubilin in the intestine
EGFP-fluorescence (hereafter referred to as cubilin-
EGFP fluorescence) was analyzed in whole mounts of
intestinal segments from Cubn+/del exon 1–6;EGFP mice.
Cubilin-EGFP fluorescence was detected in all segments
of the small intestine, i.e., duodenum, jejunum and ileum
(Figure 3).
Cubilin expression in the duodenum had not been pre-
viously reported. To substantiate this, anti-cubilin im-
munoblot analysis of intestinal extracts from wild-typeFigure 3 Cubilin expression in the intestine of Cubn+/del exon 1–6;EGFP m
whole mount segments of the duodenum (A), jejunum (B) and ileum (C) f
the ileum from a wildtype mouse subjected to epifluorscent imaging as in
segments of the intestine and kidney using antibodies to cubilin, megalin,
the luminal face of the small intestine (ileum) from a Cubn+/del exon 1–6;EGFP m
the epithelial cells of the intestinal villi shown in E. Note the mosaic patter
intestine from a Cubn+/del exon 1–6;EGFP mouse showing cubilin-EGFP express
showing segmental cubilin-EGFP expression in epithelial cells within individ
microdissected intestinal villi segments (n=4 mice) that were either predom
levels measured in EGFP-positive or EGFP-negative villi isolates were signifi
containing both EGFP-positive and EGFP-negative cells. Pound signs indicat
different (p<0.05) from levels in EGFP-negative villi.mice was performed (Figure 3D). Similar to what has
been observed in rat and canine ileal extracts [6,28],
mouse ileum and jejunum extracts contained ~460 kDa
monomer, multimer and ~200 kDa forms of cubilin.
Cubilin was also detected in extracts of the duodenum,
however the stoichiometry of the various immunoreac-
tive forms in the duodenum was different from that of
ileum and jejunum (i.e., levels of cubilin multimer >
monomer > ~200 kDa forms). The cubilin membrane
anchor, amnionless, was detected in all three segments
of the small intestine (Figure 5D). The data indicates
that multiple amnionless polypeptides are apparent in
extracts of the kidney and intestine and that their stoi-
chiometry differs between the two tissues. Amnionless
polypeptides have been previously described as having
Mr values of 35–50 kDa, which corresponds to the
range of polypeptides we observe in the intestine and
kidney. The basis for these different forms is not clear, but
may represent different posttranslational or postendocytic
modifications of the protein as has been speculated [29].
The cubilin ligand intrinsic factor was also observed in all
three segments of the small intestine (Figure 5D). Megalinice. A-C show images of EGFP fluorescence in the luminal surface of
rom a Cubn+/del exon 1–6;EGFP mouse. Inset panel c’ shows a segment of
A-C. D shows an immunoblot analysis of detergent extracts of
amnionless (Amn), intrinsic factor (IF) and tubulin. E is a DIC image of
ouse. F is an epifluorescence image showing EGFP fluorescence in
n of cubilin-EGFP fluorescence. G is a cross section of the small
ion in patches of villi. H is a high magnification view of a cluster of villi
ual villi. I is a qPCR analysis of cubilin and EGFP mRNA levels in
inantly EGFP-positive, negative or both. Asterisks indicate that mRNA
cantly different (p<0.05) from the levels in RNA prepared from villi
e that mRNA levels measured in EGFP-positive villi were significantly
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highest levels were detected in the ileum and jejunum and
lowest levels in the duodenum (Figure 3D).
In all three segments of the small intestine, cubilin-
EGFP fluorescence was found in patches of intestinal
villi, with regions of relatively strong fluorescence inter-
spersed in areas of little or no fluorescence. Closer
examination revealed that cubilin-EGFP fluorescence
was in discrete segments of each villus (Figure 3E-H).
To test the hypothesis that cubilin is monoallelically
expressed in the small intestine, we performed qPCR
analysis on microdissected villi from the ileum of
Cubn+/del exon 1–6;EGFP mice that were predominantly ei-
ther EGFP positive, EGFP negative or both. If cubilin ex-
pression were biallelic, then the mosaic pattern might be
explained by there being two populations of cells, one
with both alleles inactive (EGFP-negative) and the other
with both alleles active (EGFP-positive). If this were the
case then EGFP-positive cells would express cubilin and
EGFP mRNAs at equivalent levels. Furthermore, the
EGFP-negative cells would express neither transcript.Figure 4 Subcellular localization of cubilin, amnionless and intrinsic f
of a Cubn+/del exon 1–6;EGFP mouse ileum labeled with anti-cubilin. B is a mer
shown in A labeled with anti-cubilin and anti-EGFP together with Draq5 nu
on the apical surfaces of enterocytes. Arrows in A and B point to anti-cubil
B indicate goblet cells devoid of anti-EGFP labeling and lacking apical anti-
Cubn+/del exon 1–6;EGFP mouse ileum labeled with anti-amnionless. D is a mer
showing cubilin-EGFP expression together with Draq5 nuclear labeling. Arro
surfaces of enterocytes. Arrows in C and D point to anti-amnionless label in
image from a section of a Cubn+/del exon 1–6;EGFP mouse ileum labeled with
Cubn+/del exon 1–6;EGFP mouse intestine in E together with cubilin-EGFP expre
material present on the surfaces of both anti-EGFP-positive and anti-EGFP-n
wildtype mouse ileum labeled with anti-intrinsic factor. H is a merged imag
with the image from the EGFP channel.However, as shown in Figure 3I, predominantly EGFP-
negative cells were not only found to express cubilin
mRNA but the levels were also significantly elevated as
compared to the predominantly EGFP-positive popula-
tion. Conversely, EGFP-negative enterocytes expressed
significantly lower EGFP mRNA levels as compared to
EGFP-positive cells (Figure 3I). Based on these findings
the cubilin gene appears to be largely expressed from
one allele in intestinal cells (i.e., monoallelic expression).
We next examined sections of small intestine from
Cubn+/del exon 1–6;EGFP mice after immunolabeling with
antibodies to cubilin and EGFP. Anti-cubilin IgG-reactive
material was apparent as a discrete layer on the apical
surfaces of anti-EGFP-positive enterocytes as well as anti-
EGFP-negative enterocytes (Figure 4A, arrowheads). In
addition, anti-cubilin immunolabel was also detected
within the cytoplasm of ileal enterocytes as punctate foci
located on the apical side of the nuclei (Figure 4A, ar-
rows). This cytoplasmic staining was present in both anti-
EGFP-positive and anti-EGFP-negative enterocytes. Thus,
despite EGFP-positive enterocytes having significantlyactor in ileal enterocytes. A shows a confocal image from a section
ged image of the section of Cubn+/del exon 1–6;EGFP mouse intestine
clear staining (blue). Arrowheads in A and B point to anti-cubilin label
in label in the cytoplasm of anti-EGFP-positive enterocytes. Asterisks in
cubilin labeling. C shows a confocal image from a section of a
ged image of the section of Cubn+/del exon 1–6;EGFP mouse intestine in C
wheads in C and D point to anti-amnionless label on the apical
the cytoplasm of EGFP-positive enterocytes. E shows a confocal
anti-intrinsic factor (IF). F is a merged image of the section of
ssion. Arrowheads in E point to anti-intrinsic factor IgG-reactive
egative enterocytes. G shows a confocal image from a section of a
e of the section of the wildtype mouse intestine shown in G together
Figure 5 5Aza and TSA elicit increases in cubilin expression in NRK and Caco-2 cells. A-D, qPCR analysis of cubilin and megalin mRNA
expression in RNA isolated from NRK and Caco-2 cells cultured for 60 h with three medium changes and 84 h with four medium changes,
respectively, each containing the indicated doses of 5Aza. E-H, qPCR analysis of cubilin and megalin mRNA expression in RNA isolated from cells
cultured for 24 h with the indicated doses of TSA. Cubilin and megalin mRNA expression data were normalized to GAPDH levels. Asterisks indicate
that differences between mRNA levels in vehicle control and drug treatment groups were significant at p<0.05.
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to have similar cubilin protein levels compared to EGFP-
negative enterocytes, which have higher expression of
cubilin mRNA. These findings are consistent with the fact
that cubilin is known to be secreted and taken up by
enterocytes [30,31]. As such, enterocytes with the active
wild-type cubilin allele might express and secrete cubilin,
which could then bind to EGFP-positive enterocytes and
result in similar levels of cubilin protein in all enterocytes.
Amnionless in the intestine of Cubn+/del exon 1–6;EGFP mice
We also performed anti-amnionless labeling of sections of
small intestine from Cubn+/del exon 1–6;EGFP mice.
Amnionless immunolabeling was present on the cell sur-
face and in the cytoplasm of EGFP-positive and EGFP-
negative enterocytes (Figure 4C and D). There were no ap-
parent differences in the relative levels or in the subcellular
localization of amnionless between EGFP-positive and
EGFP-negative enterocytes. This is in contrast to what was
seen in the kidney, in which amnionless accumulated
within EGFP-positive proximal tubule cells as compared to
EGFP-negative proximal tubule cells (Figure 2F).
Intrinsic factor in the intestine of Cubn+/del exon 1–6;EGFP mice
Cubilin expressed by intestinal enterocytes mediates
binding and endocytosis of intrinsic factor-cobalamin
complex from the intestinal lumen [32]. Ileal segments
from Cubn+/del exon 1–6;EGFP mice were examined for
immunolocalization of intrinsic factor in cubilin-
EGFP-positive and cubilin-EGFP-negative enterocytes. As
shown in Figure 4E and F, intrinsic factor immunolabelingwas observed on the apical surfaces (Figure 4E, arrow-
heads) and within the cytoplasm of both EGFP-positive
and EGFP-negative enterocytes. There was no apparent
difference in the relative level of anti-intrinsic factor
immunolabel in EGFP-positive and EGFP-negative enter-
ocytes (Figure 4F). This was similar to the pattern of in-
trinsic factor immunolabeling observed in the wildtype
intestine (Figure 4G and H). Based on these observations,
the pattern of intrinsic factor uptake corresponds to anti-
cubilin immunolabel found on all enterocytes (Figure 4A),
regardless of the mosaic pattern of cubilin-EGFP or
cubilin mRNA expression.
Epigenetic regulation of cubilin
Several lines of evidence suggest that one of the two
cubilin alleles may be inactivated epigenetically in the
kidney and intestine: 1) EGFP expressed from the
targeted cubilin allele displays a distinct mosaic pattern
in the kidney and intestine, 2) proximal tubule cells ex-
pressing the targeted cubilin allele expressed little or no
cubilin and displayed reduced binding of albumin,
suggesting that the wild-type cubilin allele in these cells
was inactive, and 3) EGFP-negative enterocytes express
significantly higher levels of cubilin mRNA as compared
to EGFP-positive cells in Cubn+/del exon 1–6;EGFP mice. In-
activation of the cubilin allele might occur through epi-
genetic modifications that control the transition of
chromatin from transcriptionally active to inactive state.
Histone deacetylation and DNA methylation at CpG se-
quences are two types of epigenetic modifications that
mediate transcriptional inactivation.
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To determine whether DNA methylation regulates cubilin
transcription, we first analyzed the regions flanking the
transcription start site of the mouse cubilin gene for CpG
islands using the CpG island analysis feature of the UCSC
Genome Browser and the EMBOSS CpGPlot algorithm
[33,34]. Analysis of 5′ flanking sequences extending from
approximately −20,000 to +3,500 relative to the transcrip-
tion start site of the mouse cubilin gene did not detect any
CpG islands (data not shown). A similar analysis of the
human and rat cubilin genes using the CpG island analysis
feature of the UCSC Genome Browser did not detect any
CpG islands. These findings did not preclude the possibil-
ity that cubilin expression in these species might be
regulated by non-CpG DNA methylation [35]. It is also
possible that DNA methylation indirectly regulates cubilin
transcriptional activation.
Effects of 5Aza on cubilin in NRK and Caco-2 cells
We therefore evaluated the effects of the DNA methyla-
tion inhibitor, 5-azacytidine (5Aza), on cubilin expres-
sion in renal NRK cells and intestinal Caco-2 cells. In
NRK cells, 5Aza treatments augmented cubilin mRNA
expression as measured by qPCR (Figure 5A). In Caco-2
cells, 1 and 5 μM 5Aza treatments augmented cubilin
expression, but 10 μM 5Aza decreased cubilin expres-
sion (Figure 5C) as compared to the vehicle control.
These findings suggested that DNA methylation was
directly or indirectly regulating cubilin expression in cul-
tured renal and intestinal epithelial cells. The effect of
5Aza treatment on the expression of megalin was also
evaluated in these cells. 5Aza treatment stimulated
megalin expression in NRK cells (Figure 5B), but inhibited
megalin expression in Caco-2 cells (Figure 5D).
Effects of TSA on cubilin in NRK and Caco-2 cells
We next evaluated the effects of the histone deacetylase
(HDAC) inhibitor, trichostatin A (TSA), on cubilin mRNA
expression in NRK and Caco-2 cells. TSA treatment elic-
ited a concentration dependent increase in cubilin mRNA
expression in both cell lines (Figure 5E and G). The mag-
nitude of the effect of TSA on cubilin expression was
generally greater than that achieved using 5Aza. TSA
treatment also augmented megalin expression in both
NRK and Caco-2 cells (Figure 5F and H).
Effects of 5Aza and TSA on cubilin monoallelic expression
in PRTCs
To determine whether allelic inactivation of the cubilin
gene might be released by 5Aza or TSA treatment, we
employed primary renal tubule cells (PRTCs) isolated
from Cubn+/del exon 1–6;EGFP kidneys. Following isolation
of these cells, we consistently observed that <10% of the
cultured PRTCs were EGFP-positive which is in contrastto the approximately 1:1 ratio of EFGP-positive to
EGFP-negative cells in proximal tubules as assessed by
immunofluorescence microscopy. The basis for this ob-
servation remains to be defined but it may be an indica-
tion that cubilin deficiency in PRTCs might reduce their
migration out of tubules onto the culture plate, inhibit
adhesion to the culture plate, or reduce cell proliferation
in vitro.
The mixed population of PRTCs (i.e., EFGP-positive and
EGFP-negative PRTCs) isolated from Cubn+/del exon 1–6;EGFP
kidneys was treated with TSA. TSA treatment (10 nM)
resulted in a ~2-fold increase in cubilin mRNA levels
(Figure 6A), but the effect was reduced at higher concen-
tration. TSA treatment also increased megalin mRNA
levels (Figure 6B). Immunoblot analysis of extracts from
TSA-treated PRTCs was also performed and the results
showed that both cubilin and megalin protein expression
was augmented by the treatment (Figure 6C). Further-
more, immunoblot analysis of extracts from 5Aza treated
PRTCs was performed and the results showed that both
cubilin and megalin protein expression was augmented by
the treatment (Figure 6C).
We next reasoned that if 5Aza or TSA treatment were
able to transform cubilin monoallelic expression to
biallelic, then we should observe an increase in the num-
ber of anti-EGFP positive cells. We therefore determined
the percent of EGF-positive cells in 21 imaged fields of
DMSO treated PRTCs and in 34 imaged fields of TSA
treated (10 nM) PRTCs. As shown in Figure 6D, TSA
treatment of PRTCs did not elicit a significant change in
the percentage of anti-EGFP positive PRTCs as com-
pared to vehicle treated cells (also see Additional file 1).
Similarly, PRTCs treated with 5Aza did not lead to an
increase in the number of anti-EGFP positive cells as
compared to vehicle treated cells (data not shown). In
these 5Aza experiments, PRTC proliferation was inhibited
by 5Aza treatment to a much greater extent than was ob-
served for NRK cells. Since TSA or 5Aza treatment did
not increase the number of EGFP expressing cells, we
concluded that cubilin monoallelic expression was not
effected by either treatment. Evaluating the effects of com-
bined TSA and 5Aza was not possible due to the detri-
mental effects that the combined drugs had on PRTC
growth. For this reason, we evaluated the effects of com-
bined TSA and 5Aza treatment using NRK cells. The re-
sults showed that the stimulation of cubilin mRNA
expression achieved by combined TSA and 5Aza treat-
ment was not greater than that observed with TSA, which
consistently elicited the greatest magnitude increase (data
not shown).
Epigenetic regulation of cubilin via PPARs
The above findings suggested that TSA and 5Aza treat-
ment increased cubilin expression by increasing the
Figure 6 TSA or 5Aza treatment does not have an effect on cubilin monoallelic expression in PRTCs. A and B, qPCR analysis of cubilin and
megalin mRNA expression in RNA isolated from PRTCs treated for 7 days with DMSO or with the indicated doses of TSA. C, shows immunoblot analysis
of extracts of PRTCs treated for 7 days with vehicle or varying concentrations of TSA or 5Aza using antibodies to cubilin, megalin, and actin. D shows the
number of anti-EGFP positive cells as a fraction of total cells counted in 21 imaged fields of DMSO-treated and 34 imaged fields of 10 nM TSA-treated
PRTCs from three experiments. Asterisks indicate that differences between vehicle control and drug treatment groups were significant at p<0.05.
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are inhibited by TSA, are known co-repressors of the
transcription factors, Peroxisome Proliferator-Activated
Receptor (PPAR) [36-39]. Conversely, PPAR co-activators
increase histone acetylation, resulting in PPAR-mediated
transcription [36,38-40]. Recent studies show that the ex-
pression of PPARγ is also regulated by DNA methylation
[41] and histone deacetylation [39]. Furthermore, renal
megalin expression is known to be regulated by PPARs
[15]. We therefore tested whether epigenetic regulation of
PPARs mediated the effects of 5Aza and TSA on cubilin
and megalin expression. Computerized transcription fac-
tor binding site analysis identified three PPAR response
elements conserved in human and mouse cubilin pro-
moters (Figure 7). Analysis of cubilin promoter activity in
cells transfected with a cubilin promoter-luciferase re-
porter found that cubilin transcription was increased by
transfection of cells with PPARα and γ expression con-
structs (Figure 7B-D). Furthermore, endogenous cubilin
(and megalin) mRNA expression in NRK cells was
blocked by the PPARα and γ antagonists, GW6471 and
GW9662 (Figure 7E and F). To further evaluate the role
of PPARs in regulating cubilin expression, we utilized
PRTCs. PPARα agonist, Wy14643, treatment of PRTCs
resulted in a significant increase in cubilin protein levels
over a range of agonist concentrations (Figure 8A).Cubilin mRNA levels were also significantly increased
by PPARα agonist treatment at 100 μM concentration
(Figure 8C). By contrast, PPARα antagonist, GW6471,
significantly decreased endogenous cubilin mRNA ex-
pression and also inhibited the increased cubilin expres-
sion achieved by agonist treatment (Figure 8D). PPARα
agonist and antagonist treatments resulted in similar re-
ciprocal changes in the mRNA levels of Acadl, a known
PPARα-responsive gene [42,43] (Additional file 2). Treat-
ment of PRTCs with the PPARγ agonist (Rosiglitazone)
also resulted in a significant increase in cubilin protein
levels (Figure 8E). Rosiglitazone at 50 nM concentration
also elicited a modest, but significant increase in cubilin
mRNA expression (Figure 8G). Furthermore, the PPARγ
antagonist, GW9662, inhibited the increased cubilin ex-
pression achieved by Rosiglitazone treatment (Figure 8H).
Together, these findings indicate that, similar to megalin
[15], cubilin is a gene regulated by both PPARα and γ.
We next evaluated the effects of 5Aza and TSA on the
expression of PPARα and γ in NRK cells. As shown in
Figure 9A, 5Aza treatment elicited a dose dependent in-
crease in PPARα mRNA expression. 5Aza also augmented
PPARγ expression (Figure 9B) at low concentrations but
not at the highest concentration tested (10 μM). Similarly,
TSA treatment of NRK cells also produced a concentration
dependent increase in PPARα mRNA levels (Figure 9C).
Figure 7 PPAR regulation of cubilin expression. A, upstream flanking sequence of the mouse cubilin gene (Cubn). Putative PPAR/RXR
heterodimer binding sites, identified by Genomatix DiAlign, are indicated. Sequence elements are numbered relative to the translation start site
(+1). B, representation of the pCub −431 Luc mouse Cubn promoter construct containing mouse Cubn proximal flanking sequence (−431 to −5),
including the −97 putative PPAR/RXR binding element (shaded box), linked to a luciferase cassette. C, an established PPAR reporter construct is
transactivated by PPARα and PPARγ in transfected BN cells. Reporter plasmid (pPPRE X3-TK-luc) was cotransfected with either a PPARα expression
plasmid (pSG5 PPAR alpha), a PPARγ expression plasmid (pcDNA flag PPAR gamma) or a negative control plasmid (Con). Relative luciferase
activity in lysates from transfected cells is shown. D, PPARα and PPARγ transactivate the mouse cubilin proximal promoter. Cotransfections were
done with the pCub-431 Luc promoter plasmid and either PPARα, PPARγ, or a negative control plasmid (Con) as described for C. Relative
luciferase activity in lysates from transfected cells is shown. E and F, qPCR analysis of cubilin (Cubn) and megalin mRNA in NRK cells cultured in
the presence or absence of PPARα or PPARγ antagonists, GW6471 and GW9662 (each at 10 μM) for 24 h. Asterisks indicate p<0.05.
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centration tested (100 nM) (Figure 9D).
The observations that TSA and 5Aza increased
PPARα and γ mRNA levels suggested the possibility
that cubilin upregulation by TSA and 5Aza resulted
from increased expression of PPAR. We therefore eval-
uated the effects of PPARα and γ antagonists on TSA
and 5Aza induction of cubilin expression. As shown in
Figure 9E, the upregulation of cubilin by 5Aza wasinhibited by PPARγ antagonist as well as combined
PPARα and γ antagonist treatments. Acadl, a known
PPARα responsive gene [42,43], was also increased by
5Aza treatment and the increase was inhibited by
PPARα antagonist treatment (Additional file 2B).
These findings suggested that the 5Aza-induced ex-
pression of cubilin is dependent on 5Aza-induced
expression of PPARγ. Parallel studies showed that
5Aza-mediated induction of megalin expression was
Figure 8 PPARα and γ regulate cubilin expression in PRTCs. A shows anti-cubilin and actin immunoblot analysis of detergent extracts of
PRTCs treated with the PPARα agonist, Wy14643, at the indicated concentrations for 22 h. B shows densitometric analysis of three replicate anti-
cubilin immunoblot experiments similar to A. C shows qPCR analysis of cubilin mRNA expression in PRTCs treated with the PPARα agonist,
Wy14643, at the indicated concentrations for 22 h. D shows qPCR analysis of cubilin mRNA expression in PRTCs treated with either PPARα
agonist (100 μM), PPARα antagonist, GW6471 (10 μM), or both for 22 h. E shows anti-cubilin and actin immunoblot analysis of detergent extracts
of PRTCs treated daily with the PPARγ agonist, Rosiglitazone, at the indicated concentrations for 3 days. F shows densitometric analysis of three
replicate anti-cubilin immunoblot experiments similar to E. G shows qPCR analysis of cubilin mRNA expression in PRTCs treated daily with the
PPARγ agonist, Rosiglitazone, at the indicated concentrations for 3 days. H shows anti-cubilin and tubulin immunoblot analysis of detergent
extracts of PRTCs treated twice with PPARγ antagonist, GW9662 (10 μM), PPARγ agonist, Rosiglitazone (25 nM), or both for 36 h. Asterisks indicate
that differences between vehicle control and drug treatment groups were significant at p<0.05. Pound signs indicate that differences between
agonist treatment alone and combined agonist with antagonist treatment groups were significant at p<0.05.
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PPARα and γ (Figure 9F).
The effects of PPARα and γ antagonists on TSA-
induced cubilin expression were also evaluated. Results
showed that cubilin upregulation by TSA was inhibitedby PPARα antagonist as well as combined PPARα and γ
antagonist treatments (Figure 9G). The fact that com-
bined PPARα and γ antagonist treatment produced a
greater magnitude decrease than either antagonist alone
suggested that TSA-induced expression of cubilin is
Figure 9 5Aza and TSA elicit increases in PPARα/γ expression, and PPAR antagonists block 5Aza and TSA-mediated increase in cubilin
expression. A-B, qPCR analysis of PPARα and γ mRNA expression in RNA isolated from NRK cells cultured for 60 h with 3 medium changes each
containing the indicated doses of 5Aza. C and D, qPCR analysis of PPARα and γ mRNA expression in RNA isolated from NRK cells cultured for
24 h with the indicated doses of TSA. E and F, qPCR analysis of cubilin and megalin was performed on RNA from NRK cells treated for 36 h with
2 medium changes each containing 5 μM of 5Aza and then a 24 h treatment with 5Aza-free medium containing PPAR antagonists (each at
10 μM). G and H, qPCR analysis of cubilin and megalin mRNA in RNA isolated from NRK cells cultured for 24 h with TSA alone (100 nM) or TSA
(100 nM) plus PPAR antagonists (each at 10 μM). Cubilin, megalin and PPARα and γ mRNA levels were normalized to GAPDH. Asterisks indicate
that differences between mRNA levels in vehicle control and drug treatment groups were significant at p<0.05. Pound signs indicate that
differences between mRNA levels in drug treatment groups alone and drug treatment with PPAR antagonists were significant at p<0.05.
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and γ. Parallel studies showed that TSA-induced expres-
sion of megalin was also dependent on TSA-induced ex-
pression of both PPARα and γ (Figure 9H). Acadl levels
were also increased in response to TSA treatment and
the increase inhibited by PPAR antagonist treatment
(Additional file 2C).
We next tested whether the increased transcription of
PPARs was sufficient to induce cubilin expression or
whether the epigenetic modifiers also influenced theFigure 10 TSA-mediated increase in cubilin expression involves increase
PPARα mRNA levels in NRK cells transfected with PPARα expression construct
levels in control and PPARα were significant at p<0.05. B, qPCR analysis of cub
or a control vector and treated for 24 h with either PPARα agonist, Wy14643 (
Asterisks indicate that differences between mRNA levels in vehicle control and
that differences between mRNA levels in control vector and PPARα vector tranactivation state of PPAR. NRK cells were transfected
with a PPARα expression construct, which greatly in-
creased levels of PPARα mRNA (Figure 10A). However,
the increased PPARα levels alone did not increase
cubilin mRNA levels (Figure 10B). Similarly, the addition
of PPARα agonist alone did not alter cubilin expression
(Figure 10B). Yet the combination of PPARα over-
expression and PPARα agonist treatment caused a sig-
nificant increase in cubilin mRNA expression. These
findings indicate that under normal conditions PPARss in both PPAR transcription and activation. A, qPCR analysis of
or a control vector. Asterisk in A indicates that differences between mRNA
ilin mRNA levels in NRK cells transfected with PPARα expression construct
100 μM) , TSA (100 nM) or TSA (100 nM) plus PPARα agonist (100 μM).
drug treatment groups were significant at p<0.05. Pound signs indicate
sfected cells with the same treatments were significant at p<0.05.
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ist alone does not increase cubilin expression. Thus,
both PPARα upregulation and a PPARα agonist are re-
quired to augment cubilin expression. When control
transfected cells were treated with TSA there was a 4-fold
increase in cubilin expression (Figure 10B). The addition
of agonist to these cells did not elicit any further increase
(Figure 10B). By contrast, PPARα overexpression com-
bined with TSA treatment caused an 8-fold increase in
cubilin expression. As with controls, the addition of agon-
ist to these cells did not significantly increase the level of
cubilin expression (Figure 10B). These findings indicate
that the TSA mediated increase in cubilin expression not
only involves an increase in PPAR transcription but also
PPAR activation.
Discussion
Here we present evidence that the cubilin gene under-
goes allelic inactivation. The evidence includes findings
showing that cubilin expression in the kidneys of mice
heterozygous for targeted cubilin deletion/EGFP inser-
tion is mosaic such that some proximal tubule cells dis-
play active expression of EGFP (i.e., the targeted allele)
as well as suppressed expression of the wild-type cubilin
allele, while other proximal tubule cells display the in-
verse pattern. Mosaic expression of cubilin was also ob-
served in all three segments of the small intestine, with
cubilin-EGFP fluorescence found in discrete segments of
each villus. Additional support for enterocytes displaying
allelic inactivation of the cubilin gene came from qPCR
studies of Cubn+/del exon 1–6;EGFP mice showing that
cubilin mRNA levels were significantly reduced in iso-
lated regions of the small intestine expressing EGFP as
compared to non-EGFP expressing regions. At the protein
level, unlike what was seen in the kidney, enterocytes
displayed both expression of the cubilin allele bearing the
targeted deletion/EGFP insertion and contained immuno-
logically detectable cubilin. Since enterocytes have been
shown to release cubilin in association with extracellular
surfactant-like particles [31], which bind to the apical por-
tion of the cell [30], it is reasonable to expect that cubilin
expressed in some enterocytes from the wild-type cubilin
allele is being released and taken up via cubilin binding re-
ceptors (e.g., megalin and/or amnionless) expressed by
enterocytes in which the wild-type cubilin allele is
suppressed. Furthermore, this form of cubilin appears to
be capable of endocytosis of its ligand, intrinsic-factor co-
balamin complex, since intrinsic factor uptake was similar
in enterocytes with suppressed wild-type cubilin allele and
those with an active wild-type cubilin allele.
Unlike what was observed in the kidney where
amnionless accumulates intracellularly in cubilin-deficient
cells, the consequences of cubilin deficiency on amnionless
trafficking in intestinal cells was not clear. Based on ourintestinal data, we speculated that a secreted form of intes-
tinal cubilin might act in a non-cell autonomous manner
to prevent the accumulation of amnionless in enterocytes
having lower endogenous cubilin expression. It is also im-
portant to point out that the intestine appears to express
multiple cubilin and amnionless isoforms, which have
different stoichiometries in the kidney (Figure 3D).
Therefore, it is possible that in the intestine, cubilin and
amnionless trafficking to the apical cell membrane are
not interdependent.
The finding that 5Aza and TSA treatments were un-
able to release the suppression of the silenced cubilin
allele suggests that DNA methylation and histone
deacetylation may not be the only mechanisms of regu-
lation of cubilin monoallelic expression. Indeed, diverse
mechanisms exist to mediate allelic inactivation includ-
ing interplay of DNA modifications by DNA methylation
and modifications of the histone proteins by acetylation,
methylation, SUMOylation or phosphorylation [44,45].
Additionally, imprinted monoallelic expression of certain
gene clusters is in part mediated by noncoding RNAs
under the control of methylation of imprint control ele-
ments [44]. Intriguingly, the cubilin gene is located in
the mouse chromosome 2 proximal region, which is one
of several chromosomal regions known to contain genes
that undergo parental imprinting during development
[46,47]. Our observation that groups of adjacent prox-
imal tubule cells shared the same inactive cubilin allele
suggests that the allelic inactivation is inherited clonally
from a progenitor that underwent imprinting during
development. Further research will be required to define
the precise mechanisms regulating cubilin monoallelic
expression.
Since cubilin monoallelic expression was unaltered by
5Aza and TSA treatments, we concluded that the in-
creased cubilin mRNA levels were due to effects of these
agents on the transcriptionally active cubilin allele. Both
histone deacetylation and DNA methylation are associ-
ated with PPAR repression [39,41]. In fact, HDAC1 and
3 are known PPARγ co-repressors [48-50]. Conversely,
PPAR co-activators, such as CBP/p300 and SRC-1, possess
histone acetylase activity required for chromatin remodel-
ing to allow PPAR-mediated transcription [39,40,51,52].
Furthermore, recent findings show that the cubilin
coreceptor, megalin, is a PPAR-responsive gene and its
expression is augmented through inhibition of histone
deacetylation [15,16]. In light of these studies, we recog-
nized the possibility that the observed effects of TSA and
5Aza on cubilin might also involve PPAR induction. This
led us to discover that the observed effects of 5Aza and
TSA on cubilin expression were dependent on PPARα
and γ induction. Specifically, we showed that cubilin was a
PPARα and γ responsive gene, that the expression of
PPARα and γ was inducible by 5Aza and TSA alone, and
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were dependent on increased expression of PPARα and γ.
Similarly, we showed that TSA and 5Aza-induced megalin
expression was dependent on increased expression of
PPARα and γ.
While TSA and 5Aza treatments augmented PPAR
and cubilin mRNA levels, no significant increase in
cubilin levels was achieved by overexpressing PPARα in
the absence of PPARα agonist. Therefore, the effects of
TSA and 5Aza on cubilin mRNA levels cannot be attrib-
uted to increased PPAR mRNA levels alone. We in-
ferred that, in addition to increasing PPAR expression,
5Aza and TSA treatments must also lead to PPAR acti-
vation. The underlying mechanism for the apparent
agonist-independent effects of TSA on induction of
PPAR-dependent transcription of cubilin remains to be
established. TSA and/or 5Aza might augment levels of
endogenous PPAR agonists, cause demethylation of sites
on the cubilin gene, or reduce histone occupancy of the
cubilin promoter. Any of these effects might be
sufficient for promoting PPAR action in an agonist-
independent manner. Since HDACs are known co-
repressors and HATs are co-activators of PPARs [39], it
is reasonable to expect that inhibiting HDAC activity
will shift PPARs towards a more active state. In fact,
HDAC inhibitors have been reported to act as atypical
PPAR agonists [38] and studies have shown that inhib-
ition of HDACs stimulates transcription of PPAR
responsive genes [48,53]. Therefore, it is likely that in-
creased acetylation of histones associated with the
cubilin promoter in response to HDAC inhibitor treat-
ment is sufficient to promote PPAR-driven cubilin
expression.
Our findings that cubilin and megalin expression is
regulated by DNA methylation and histone deacetylation
raise questions as to whether these genes might be
predisposed to inactivation by disease-associated in-
creases in DNA methylation and histone deacetylation.
DNA methylation is a major contributing factor to vari-
ous disease-related processes, such as tumorigenesis,
atherogenesis and diabetic nephropathy [54-56] (includ-
ing glomerular and interstitial fibrosis [57]). Global DNA
hypermethylation is associated with inflammation and
increased mortality in chronic kidney disease [58] and
chronic inflammation has even been implicated as a
driving factor associated with increased DNA methyla-
tion in diseases such as chronic gastritis and gastric
cancer [59,60]. Furthermore, the inflammatory cytokine,
IL-6, exerts an impact on epigenetic changes in cells via
regulation of DNA methyltransferase [61]. Histone
deacetylation catalyzed by HDACs also contributes to
the pathogenesis of various diseases including gastric
and colorectal cancer [62,63], renal disease such as poly-
cystic kidney disease [64] and macrophage infiltrationand fibrotic changes associated with tubulointerstitial
injury [65].
HDAC inhibitors appear to have significant thera-
peutic potential in kidney disease [66]. For example, a
number of studies have demonstrated efficacy of TSA in
ameliorating renal injury in mice following unilateral ur-
eteral obstruction [65], nephrotoxic serum nephritis [67]
and in lupus pathogenesis [68]. In light of findings
presented herein, it is possible that drugs that inhibit
HDACs might ameliorate renal disease by releasing epi-
genetic suppression of PPARs, cubilin and megalin. In-
triguing new findings from rodent studies highlight the
potential reno-protective benefits of increased megalin
expression on early phase renal injury in responses to
protein overload [15]. Specifically, the studies showed
that megalin expression in rats is decreased by BSA
overload and that augmenting megalin expression in rats
by PPARγ agonist treatment correlated with a reduction
in BSA-induced proteinuria. Effects of PPAR agonist
treatments on renal expression of the albumin receptor,
cubilin, were not evaluated in those studies. Thus, it was
not clear whether the mechanistic basis for the observed
effects involved PPAR agonist induced changes in cubilin
expression. Our studies demonstrate that cubilin, like
megalin, is under PPAR transcriptional regulation and
suggest that the amelioration of protein overload-induced
albuminuria by PPAR agonists observed in other studies is
mediated by augmented levels of cubilin.
Conclusions
Cubilin expression is epigenetically regulated by at least
two processes. The first process involves allelic inactiva-
tion that is not reversible by inhibiting DNA methylation
and histone deacetylation. The second process involves
transcriptional regulation of cubilin by PPAR transcrip-
tion factors that are themselves regulated by DNA
methylation and histone deacetylation.
Methods
Animals
All studies involved the use of 1–6 month old male mice
heterozygous for cubilin exon 1–6 deletion with an
EGFP cassette insertion (Cubn+/del exon 1–6;EGFP) [17] or
age/sex matched wildtype littermates. Mouse experimen-
tation was conducted with approval from the IACUC.
Antibodies
Goat anti-cubilin IgG (A20) was purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA), rabbit anti-
EGFP IgG was from Abcam (Cambridge, MA), goat
anti-albumin was obtained from Bethyl Laboratories,
Inc. (Montgomery, TX), mouse anti-human α-tubulin
was purchased from Sigma-Aldrich (St. Louis, MO) and
rabbit anti-actin was from Abcam. Rabbit anti-human
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David H. Alpers (Washington University School of
Medicine, St. Louis, MO). Rabbit anti-porcine megalin
(rb6286) was described previously [69]. Antiserum to
ammnionless (rb4156/57) was prepared by immunizing
rabbits with synthetic multiple antigenic peptide con-
taining amino acid residues 165–178 (accession number
NM_001108061.1). The resulting antiserum reacted with
a single ~45 kDa polypeptide in mouse kidney extracts
and ~35 kDa and 30 kDa bands in intestinal extracts and
an ~30 kDa band in extracts of E8.5 mouse embryo ex-
tracts and rat BN cells (Figure 3D and data not shown).
Donkey anti-goat and donkey anti-rabbit-Alexa Fluor (488
or 568) conjugates were purchased from Invitrogen
(Carlsbad, CA).
Tissue procurement and immunofluorescence
Following euthanization, animals were perfused first
with phosphate-buffered saline (PBS) and then with 4%
paraformaldehyde, PBS. Tissues were dissected and fur-
ther fixed by immersion in 4% paraformaldehyde PBS
for 12 h. For kidney immunohistochemical analysis,
~0.25 cm thick strips of cortex tissue were isolated. For
small intestine immunohistochemical analysis, ~10 cm
long segments of duodenum (extending distally from the
fundus of the stomach), jejunum (beginning ~5 cm from
the end of duodenum) and ileum (ending ~2 cm superior
of the cecum) were isolated. Isolated tissues were embed-
ded in paraffin and sectioned at 6 μm thickness. Tissue
sections were incubated with primary antibodies diluted in
PBS containing 3% BSA, washed with PBS and incubated
with Alexa Fluor conjugated secondary antibodies. Nuclei
were stained using Draq5 (Cell Signaling Technology,
Danvers, MA). Labeled sections were analyzed using a
Leica SP5 confocal microscope (Leica Microsystems Inc.,
Exton, PA)using the 63× objective or a Zeiss Axio M2
microscope using the 40× objective. Whole mount images
of unlabeled intestine EGFP-fluorescence were taken by a
Leica MZ FLIII microscope at ~5× magnification.
Intestinal villi from Cubn+/del exon 1–6;EGFP mouse
ileum were micro-dissected under GFP light at 10× mag-
nification using Leica MZ FLIII microscope. Villi that
appeared predominantly EGFP-positive or EGFP-negative
as well as a random sampling of both were separately iso-
lated using dissection scissors in Hank’s buffered salt solu-
tion (HBSS) (Thermo Scientific) containing 4% FBS. Villi
were then briefly span down, the supernatant removed
and RNA extracted from the samples using the RNeasy
Plus Mini Kit (QIAGEN, Valencia, CA). qPCR was
performed as described below.
Immunoblot analysis
Unfixed segments of small intestine were homogenized
in 1% Triton X-100, 0.5% Tween20, 0.5 M NaCl, 50 mMHepes, pH 7.5 containing a protease inhibitor cocktail
(Complete-mini, EDTA-free, Roche, Germany) using a
Polytron-aggregate (Brinkmann Instruments, Switzerland).
Extracts were subjected to centrifugation at 100 K × g for
30 min at 4°C. Protein concentration in extracts was
quantified using Pierce BCA Protein Assay Kit (Rockford,
IL). Equal amounts of protein from the extracts were
loaded onto NuPAGE 4-12% polyacrylamide gradient, Bis-
Tris gels in the presence of SDS (no reducing agent). Fol-
lowing electrophoresis, the proteins were transferred onto
PVDF membranes, which were blocked with 5% non-fat
milk in TBS and probed with primary and secondary anti-
bodies diluted in TBS containing 0.5% Tween 20 and 5%
non-fat milk. Chemiluminescent detection of bound
antibodies was achieved using the Pierce ECL Western
Blotting Substrate.
Cell culture
NRK-52E (NRK) (ATCC no. CRL-1571) and Caco-2
(ATCC no. HTB-37) cells were cultured in DMEM (high
glucose) with 10% fetal bovine serum, Glutamax (Life
Technologies, Grand Island, NY), non-essential amino
acids, 100 units/ml penicillin, and 100 units/ml strepto-
mycin (Thermo Scientific, Rockford, IL), and maintained
at 37°C and 5% CO2. For trichostatin A (TSA) treat-
ments, cells were plated at 1.0 × 104 cells/cm2 for 6 h,
and subsequently treated for 24 h with 10, 50 or 100 nM
TSA (Sigma, St. Louis, MO) (281.6 pM final DMSO
concentration in medium). For 5-Azacytidine (5Aza)
treatments, NRK cells were plated at 5 × 103 cells/cm2
for 6 h and subsequently treated with 1, 5 or 10 μM
5Aza (Sigma) (281.6 pM final DMSO concentration in
medium) for 60 h with three media changes at 0, 12 and
36 h. For Caco-2 cells, 5Aza treatments were for 84 h
with four media changes at 0, 12, 36 and 60 h. To evalu-
ate the effects of PPAR transcription factor antagonists
on TSA treated cells, TSA treated NRK cells were incu-
bated with PPARα antagonist (GW6471), PPARγ antag-
onist, (GW9662) (Sigma), or both, each at 10 μM for
24 h. To evaluate the effects of PPAR transcription fac-
tor antagonists on 5Aza treated cells, NRK cells were
treated for 36 h with 5Aza and incubated with 5Aza-free
medium containing PPAR antagonists, each at 10 μM
for 24 h. In studies evaluating the effects of transgenic
PPARα, NRK cells were transiently transfected with pSG5
PPAR alpha plasmid [70] (plasmid 22751; Addgene,
Cambridge, MA) using Lipofectamine LTX & PLUS Re-
agent (Invitrogen) according to manufacturer’s instruc-
tions. Nearly confluent NRK cells, grown in six-well
plates, were transfected with 1 μg pSG5 PPAR alpha plas-
mid or a control plasmid using Lipofectamine LTX at a
1:3 mass:volume ratio for ~18 h. The cells were then
allowed to grow for 24 h in complete medium and treated
with TSA or vehicle as described above.
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cultured as described previously [71,72]. Briefly, mouse
renal cortices were dissected and minced in ice-cold dis-
section solution of Hank’s buffered salt solution (HBSS)
(Thermo Scientific) supplemented with 10 mM glucose,
5 mM glycine, 1 mM alanine and 15 mM HEPES pH
7.4. The minced fragments were transferred to a dissec-
tion solution containing 96 μg/ml soybean trypsin in-
hibitor, 1 mg/ml type 1 collagenase and 0.05% type 2
collagenase, and digested for 30 min at 37°C. After di-
gestion, the mixture was passed through a 250 μm pore
size nylon sieve and the flow-through material passed
through an 80 μm pore size nylon sieve. Proximal tubules
(PT) retained on the 80 μm sieve were resuspended with
37°C HBSS solution containing 1% BSA and then
subjected to centrifugation for 5 min at 170 × g. The PT
pellet was resuspended in 1:1 mixture of DMEM:F12 cul-
ture medium containing 15 mM HEPES and 2 mM L-glu-
tamine (Thermo Scientific) supplemented with 9% FBS, 50
nM hydrocortisone, ITS (BD Biosciences, San Jose, CA),
sodium pyruvate, non-essential amino acids, 100 units/ml
penicillin, and 100 units/ml streptomycin (Thermo Scien-
tific), and then plated and maintained at 37°C and 5%
CO2. PRTCs were cultured for 4 days before treatment
with a medium change every other day. PRTCs were then
treated with 5Aza or TSA or DMSO (vehicle)-containing
medium for additional 7 days. On day 7, PRTCs were used
for protein or RNA extraction using the RNeasy Plus Mini
Kit (QIAGEN, Valencia, CA) or fixed in 4% paraformalde-
hyde PBS with 1% Triton-X100 for 20 min for immuno-
fluorescent microscopy.
For PPAR agonist and antagonist studies, semi-
confluent PRTC cultures were treated with PPAR alpha
agonist, Wy14643 (Cayman Chemical Company, Ann
Arbor, MI), PPAR alpha antagonist, GW6471 (Sigma) or
vehicle DMSO only at the indicated concentrations for
22 hrs in complete media containing 3%FBS. Protein or
RNA was extracted from independent experiments as
already described.
qPCR
RNA from cells or tissue was isolated using the RNeasy
Plus Mini Kit (QIAGEN, Valencia, CA) and quality
assessed on an Agilent Bioanalyzer. cDNA was prepared
from 0.25-1 μg total RNA using the iScript cDNA
Synthesis Kit (Bio-Rad, Hercules, CA) according to
manufacturer instructions. qPCR was performed using
iQ SYBR Green Supermix (Quanta BioSciences, Inc.,
Gaithersburg, MD) reagents and a C1000 Thermal Cycler
(Bio-Rad). The relative values for each gene were deter-
mined using the cycle thresholds and normalized to refer-
ence genes. The following qPCR primers were used: rat
Cubilin forward, 5′-TGGGAGCTGCGTCTATGATT-3′
and rat Cubilin reverse, 5′- AAGGAAGTTGCCGGAAGAGA-3′ (NM_053332.2); rat Megalin/Lrp2 forward,
5′- ATCTGTGCTCCAGGTCCAAA-3′ and rat Megalin/
Lrp2 reverse, 5′-ATTGAGGCAGGTGAACTGGA-3′
(NM_030827.1); rat Pparα forward, 5′- GGCCAAGAGA
ATCCACGAAG-3′ and rat PPARα reverse, 5′- ACAAA
AGGCGGATTGTTGCT-3′ (NM_013196.1); rat Pparγ
forward, 5′- GGTGAAACTCTGGGAGATCCT-3′ and
rat PPARγ reverse, 5′- CATGGTAATTTCTTGTGAAG
TGCT-3′ (NM_013124.3); rat Gapdh forward, 5′- GT
GCCAGCCTCGTCTCATA-3′ and rat Gapdh reverse,
5′- AGGTCAATGAAGGGGTCGTT-3′ (NM_017008.3);
rat/mouse Rn18s forward, 5′- CGCCGCTAGAGGTG
AAATTCT-3′ and rat/mouse Rn18s reverse, 5′- CGA
ACCTCCGACTTTCGTTCT-3′ (NR_046237.1); human
Cubilin forward, 5′- CCTGAACTGCGAATGGACTC-3′
and human Cubilin reverse, 5′- CATCACCCACTCGAA
ACTCG-3′ (NM_001081.3); human Lrp2 forward, 5′-
GATTGGGCTGCTTCACGATT-3′ and human Lrp2 re-
verse, 5′- ATGGCAAGTCCAAACGGATG-3′ (NM_004
525.2); human Gapdh forward, 5′- ATGTTCGTCAT
GGGTGTGAA-3′ and human Gapdh reverse, 5′- GG
TGCTAAGCAGTTGGTGGT-3′ (NM_002046.4); mouse
Cubilin forward, 5′-ATTTTCTCTGGGGTTTTGTTAC-
3′ and mouse Cubilin reverse, 5′-TAAGTTTCCCT
CCTCCGTAG-3′ (NM_001081084.2); mouse Megalin/
Lrp2 forward, 5′-TGACTGCGGAGACATGAGTG-3′
and mouse Megalin/Lrp2 reverse, 5′-CACAGACCCA
GTGTTGTGGA-3′ (NM_001081088.1); mouse Gapdh
forward, 5′-CAGCCTCGTCCCGTAGACA-3′ and mouse
Gapdh reverse, 5′-CAACAATCTCCACTTTGCCACT-3′
(NM_008084.2); mouse βactin forward, 5′-AACCGCTC
GTTGCCAATA-3′ and mouse βactin reverse, 5′-CG
GGACCTGACAGACTACCTC-3′ (NM_008084.2); and
GFP forward, 5′-CAACAGCCACAACGTCTATATCA
TG-3′ and GFP reverse, 5′-ATGTTGTGGCGGATCT
TGAAG-3′ (U50963.1) [73].
Cubilin promoter luciferase transfection assays
BN cells for luciferase reporter assays were passaged in
complete medium (MEM with 10% fetal bovine serum,
Glutamax (Life Technologies, Grand Island, NY), non-
essential amino acids, 100 units/ml penicillin, and 100
units/ml streptomycin (Thermo Scientific) as described
previously [8]. Prior to transfection, BN cells were plated
at 0.5 ×105 cells/cm2 in 24-well culture dishes in complete
medium and grown overnight. Control transfections were
performed with PPARα (pSG5 PPAR alpha), PPARγ
(pcDNA flag PPAR gamma; Plasmid 8895, Addgene) [74]
or pcDNA3.1(+) (Life Technologies, Grand Island, NY)
expression plasmids in combination with a PPAR respon-
sive luciferase reporter plasmid (PPRE X3-TK-luc; Plasmid
1015, Addgene) [75]. Experimental transfections were
conducted with PPARα, PPARγ or pcDNA3.1(+) expres-
sion plasmids in combination with a cubilin promoter
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of a mouse cubilin promoter fragment (−431 to −5,
relative to the translation start site) into the pGL3-Basic
luciferase reporter plasmid (Promega, Madison, WI).
Transfections were performed in triplicate with Gene-
PORTER 2 (Genlantis, San Diego, CA) using 1.5 μg of
each plasmid (3 μg total) and 15 μl GenePORTER 2 per
transfection. Transfections proceeded for 24 h after which
cells were lysed and extracts prepared for luciferase assay
with the BD Monolight Enhanced Luciferase Assay Kit
(BD Biosciences, San Jose, CA) according to manufacturer
recommendations. Luciferase activity was measured using
a Monolight 2012 Luminometer (BD Biosciences).
Statistical analysis
Data are presented as mean ± SD of 3 replicates, repre-
sentative of at least 3 independent experiments. Two-
tailed Student’s t-tests were used to compare control
and treatment groups.
Additional files
Additional file 1: A-C, show confocal images of anti-EGFP and anti-
cubilin labeled renal proximal tubules cells isolated from the cortex
of Cubn+/del exon 1–6;EGFP mouse kidneys and treated for 24 h
with DMSO vehicle. D-F, show confocal images of anti- EGFP and anti-
cubilin labeled cells isolated from the renal cortex of Cubn+/del exon 1–6;
EGFP mouse kidneys and treated for 24 h with TSA (10 nM). Nuclei (blue)
were stained using Draq5.
Additional file 2: A, qPCR analysis of Acadl mRNA expression in
PRTCs treated with PPARα antagonist, GW6471 (10 μM), PPARα
agonist (100 μM), or both for 22 h. B, qPCR analysis of Acadl was
performed on RNA from NRK cells treated for 36 h with 2 medium
changes each containing 5 μM of 5Aza and then a 24 h treatment with
5Aza-free medium containing PPAR antagonists (each at 10 μM). C, qPCR
analysis of Acadl mRNA in RNA isolated from NRK cells cultured for 24 h
with TSA alone (100 nM) or TSA (100 nM) plus PPAR antagonists (each at
10 μM).
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